| Fiscal Year End | Company Status | Exempt Flag |
| July 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 10/Apr/1972 | 11/Apr/2024 | Canada | | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Biotechnology/Biopharmaceutical
| ABOUT IBEX (From News Release July 3, 2013)
The Company, through its wholly owned subsidiaries, IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products Inc. (North Liberty, IA), manufactures and markets enzymes for biomedical use. IBEX also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *IBT | *IBEX Technologies Inc | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *IBEX Technologies Inc. | 19/Dec/2007 | 11/Apr/2024 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
